News Features Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question L.A. McKeown August 09, 2024
News Daily News COVID-19 Vaccination Tied to Fewer CV Events in Large UK Study Todd Neale August 01, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2024 Shelley Wood July 31, 2024
News Daily News Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF Michael O'Riordan July 09, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2024 Shelley Wood July 02, 2024
News Daily News Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years Yael L. Maxwell June 26, 2024
News Daily News Knowns and Unknowns in Subclinical Aortic Valve Thrombosis Caitlin E. Cox June 21, 2024
News Daily News Another Low-Cal Sugar Substitute Linked to Cardiovascular Risks L.A. McKeown June 12, 2024
News Daily News Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift Yael L. Maxwell May 03, 2024
News Daily News Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI Michael O'Riordan March 26, 2024
News Conference News CRT 2024 Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries L.A. McKeown March 14, 2024
News Conference News ISC 2024 AI-Based System Boosts Quality of Stroke Care and Reduces Events Todd Neale February 16, 2024
News Conference News ISET 2024 AI Tools to Meet Every Need? The Future of Vascular Medicine Caitlin E. Cox February 02, 2024
News Daily News FDA Approves First Transcatheter Tricuspid Valve Replacement Device L.A. McKeown February 02, 2024
News Daily News DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants Shelley Wood January 17, 2024
News Daily News Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2 Michael O'Riordan January 03, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial Michael O'Riordan December 27, 2023